검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Alpelisib |
Overview Company | Fondazione per la Medicina Personalizzata |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target synergy, effectively inhibits the PI3K pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 9 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.. This phase IB/II study assessed safety, pharmacokinetics, and efficacy of alpelisib, a selective PI3Kα inhibitor, plus weekly paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer (GC). In phase IB, patients with advanced solid tumors re… |
Clinical Primary efficacy | ORR 43.3% |
Clinical ORR | 43.3% |
Clinical Result source | ClinicalTrials.gov NCT01923168 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Alpelisib |
Overview Company | Fondazione per la Medicina Personalizzata |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Gastrointestinal Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | target synergy, effectively inhibits the PI3K pathway |
MoA Biomarker | HER2- positive |
PK/PD Half-life | 9 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.. This phase IB/II study assessed safety, pharmacokinetics, and efficacy of alpelisib, a selective PI3Kα inhibitor, plus weekly paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer (GC). In phase IB, patients with advanced solid tumors re… |
Clinical Primary efficacy | ORR 43.3% |
Clinical ORR | 43.3% |
Clinical Result source | ClinicalTrials.gov NCT01923168 |
Clinical Data Tier / Score | A · 28 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교